News & Videos - MABVAX THERAPEUTICS HOLDINGS

...

MabVax Therapeutics and Boehringer Ingelheim Sign Asset Purchase and License Agreement and Related Agreements for an Antibody Development Program Targeting Multiple Solid Tumor Cancers PR Newswire SAN DIEGO, July 9, 2018 SAN DIEGO , July 9, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage oncology drug development company and Boehringer Ingelheim today announced they have signed an asset acquisition and related agreements centered on MabVax's program...

MabVax Therapeutics' HuMab-5B1 ImmunoPET Imaging Agent MVT-2163 Subject of National Institutes of Health R01 Research Grant Awarded to Memorial Sloan Kettering Cancer Center - Grant intended to evaluate the utility of MVT-2163 to improve pre-operative staging of patients with pancreatic cancer PR Newswire SAN DIEGO, July 6, 2018 SAN DIEGO , July 6, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc . (Nasdaq: MBVX), a clinical-stage oncology drug development company, announced today that...

MabVax Therapeutics Receives Nasdaq Delist Determination PR Newswire SAN DIEGO, July 5, 2018 SAN DIEGO , July 5, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today that as a result of the Company's decision not to submit a plan to regain compliance with Nasdaq's...

MabVax Therapeutics Grants Exclusive Sublicense to Y-mAbs Therapeutics for Patented Neuroblastoma Vaccine PR Newswire SAN DIEGO, July 3, 2018 SAN DIEGO , July 3, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical stage oncology drug development company has granted to Y-mAbs Therapeutics, Inc., a privately held clinical stage biopharmaceutical company, an exclusive sublicense to a bi-valent ganglioside based vaccine intended to treat neuroblastoma, a rare pediatric...

MabVax Therapeutics Decides Not to Submit Plan to Regain Compliance with Nasdaq Listing Standards PR Newswire SAN DIEGO, July 2, 2018 SAN DIEGO , July 2, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today the Company's board of directors voted on June 29, 2018 not...

MabVax Therapeutics Receives Superseding Letter Related to the Late Filing of Form 10-Q PR Newswire SAN DIEGO, June 27, 2018 SAN DIEGO , June 27, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today the Company received a superseding letter from Listing...

MABVAX INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In MabVax Therapeutics Holdings, Inc. To Contact The Firm PR Newswire NEW YORK, June 8, 2018 NEW YORK , June 8, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MabVax Therapeutics Holdings, Inc. ("MabVax" or the "Company") (NASDAQ: MBVX). If you invested in MabVax stock or options and would like to discuss...

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against MabVax Therapeutics Holdings (MBVX) & Lead Plaintiff Deadline - August 3, 2018 PR Newswire NEW YORK, June 5, 2018 NEW YORK , June 5, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against MabVax Therapeutics Holdings ("MabVax" or the "Company") (NASDAQ: MBVX) and certain of its officers, on behalf of...

MabVax Class Action: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against MabVax Therapeutics Holdings, Inc. - MBVX PR Newswire NEW YORK, June 5, 2018 NEW YORK , June 5, 2018 /PRNewswire/ -- Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of MabVax Therapeutics Holdings, Inc. ("MabVax" or the "Company") (NASDAQ: MBVX) between March 14, 2016 and May 18, 2018...

MabVax Therapeutics Receives Nasdaq Notification Due to Late Form 10-Q PR Newswire SAN DIEGO, May 24, 2018 SAN DIEGO , May 24, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today that, as expected, the Company received notice from the Listing Qualifications...

MabVax Therapeutics Receives U.S. Patent for Fully Human Antibodies Targeting the Antigen GD2 Expressed on Sarcoma, Melanoma, and Neuroblastoma - Company expands intellectual property estate with granted patent on antibodies that have been evaluated in preclinical studies as both a therapeutic product and a diagnostic agent PR Newswire SAN DIEGO, May 17, 2018 SAN DIEGO , May 17, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc . (Nasdaq: MBVX), a clinical-stage biotechnology company with a...

MabVax Therapeutics Presentation from VirtualInvestorConferences.com Now Available for On-Demand Viewing PR Newswire SAN DIEGO, May 7, 2018 - Company invites individual and institutional investors as well as advisors to log on to VirtualInvestorConferences.com to view presentation - SAN DIEGO , May 7, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc . (NASDAQ: MBVX), a clinical-stage oncology drug development company, today announced that the May 3 rd presentation from David Hansen ,...

MabVax Therapeutics Holdings, Inc. Announces Private Placement Offering PR Newswire SAN DIEGO, May 3, 2018 SAN DIEGO , May 3, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced it has entered into securities purchase agreements with accredited investors pursuant to which the Company has agreed to sell $860,000...

MabVax Therapeutics to Present an Interactive Live Webcast at VirtualInvestorConferences.com PR Newswire SAN DIEGO, April 30, 2018 - Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual event on May 3rd at 10:45 a.m. EDT - SAN DIEGO , April 30, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc . (NASDAQ: MBVX), a clinical-stage oncology drug development company, today announced that David Hansen , MabVax's President and Chief...

MabVax Therapeutics Antibody Program Results Featured in Three Presentations at 2018 American Association for Cancer Research (AACR) Annual Meeting - Interim results from Phase 1 clinical trial of MVT-1075, demonstrated a dosing strategy for the clinical translation of a radioimmunotherapy product for the treatment of patients with relapsed / refractory pancreatic and other CA19-9 positive cancers - Preclinical Results on a fully human antibody demonstrated high binding selectivity to Tn and sTn...

MabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaq's Minimum Stockholders' Equity Requirements - No immediate effect on the Company's Nasdaq listing or the trading of its common stock - PR Newswire SAN DIEGO, April 13, 2018 SAN DIEGO , April 13, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc . (NASDAQ: MBVX), a clinical-stage oncology drug development company, today announced that it received a letter from the Listing Qualifications Department of the NASDAQ Stock...

MabVax Therapeutics Reports 2017 Operational and Financial Results and 2018 Milestones - 2017 marked by clinical advancement of treatments for various cancers - - Management on track to execute value-driving corporate and clinical milestones in the first half of 2018 - - Company expects to complete one or more strategic transactions with third parties that are intended to unlock significant value in 2018 - PR Newswire SAN DIEGO, April 2, 2018 SAN DIEGO , April 2, 2018 /PRNewswire/ -- MabVax...

MabVax Therapeutics Announces Acceptance of Three Poster Presentations at the 2018 American Association for Cancer Research (AACR) Annual Meeting - Company to present interim results from the Phase 1 clinical trial of MVT-1075, a radioimmunotherapy product for the treatment of patients with relapsed / refractory pancreatic cancer - Company to present results from preclinical work on a fully human antibody that binds to Tn and sTn antigens that are expressed on ovarian and breast cancers -...

MabVax Therapeutics Regains Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement PR Newswire SAN DIEGO, March 6, 2018 SAN DIEGO , March 6, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today that it received a letter from the Listing Qualifications Department of The NASDAQ Capital Market...